Literature DB >> 10229797

Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK.

A Zaballos1, J Gutiérrez, R Varona, C Ardavín, G Márquez.   

Abstract

Thymus-expressed chemokine (TECK) has been reported to chemoattract dendritic cells, thymocytes, and activated macrophages. Here, we show that TECK is a specific agonist for a human orphan receptor called GPR-9-6. We have determined the cDNA sequence of human GPR-9-6 and cloned the corresponding murine cDNA. Human and murine GPR-9-6 expression is very high in the thymus and low in lymph nodes and spleen. RT-PCR analysis of murine GPR-9-6 expression on murine FACS-sorted thymocyte subpopulations showed that this gene is expressed in both immature and mature T cells. Additions of human or murine TECK to HEK 293/human GPR-9-6 and HEK 293/murine GPR-9-6 transfectants provoked intracytoplasmic calcium mobilization. Human TECK also induced the in vitro migration of HEK 293/human GPR-9-6 cells. These results confirm that GPR-9-6 is a specific receptor for TECK. According to the established nomenclature system, we propose to rename GPR-9-6 as CC chemokine receptor 9 (CCR9).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system.

Authors:  O Yoshie
Journal:  Springer Semin Immunopathol       Date:  2000

2.  The Role of Integrin Expressing Cells in Modulating Disease Susceptibility and Progression (January 2016).

Authors:  Aftab A Ansari; Siddappa N Byrareddy
Journal:  Int Trends Immun       Date:  2016-01

3.  Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis.

Authors:  Joshua Abd Alla; Andreas Langer; Sherif S Elzahwy; Gökhan Arman-Kalcek; Thomas Streichert; Ursula Quitterer
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 4.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

5.  Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.

Authors:  R M Scoggins; J R Taylor; J Patrie; A B van't Wout; H Schuitemaker; D Camerini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Expression of mucosal chemokines TECK/CCL25 and MEC/CCL28 during fetal development of the ovine mucosal immune system.

Authors:  François Meurens; Julia Whale; Robert Brownlie; Tova Dybvig; David R Thompson; Volker Gerdts
Journal:  Immunology       Date:  2007-01-22       Impact factor: 7.397

Review 7.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

8.  Inverse relationship between dendritic cell CCR9 expression and maturation state.

Authors:  Maureen L Drakes; Patrick J Stiff; Thomas G Blanchard
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

9.  Abnormal regulation of chemokine TECK and its receptor CCR9 in the endometriotic milieu is involved in pathogenesis of endometriosis by way of enhancing invasiveness of endometrial stromal cells.

Authors:  Yun Wang; Jing Yu; Xuezhen Luo; Xiaoqiu Wang; Mingqing Li; Ling Wang; Dajin Li
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

10.  Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation.

Authors:  Caroline Schmutz; Alison Cartwright; Helen Williams; Oliver Haworth; John H H Williams; Andrew Filer; Mike Salmon; Christopher D Buckley; Jim Middleton
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.